TW287949B - - Google Patents

Info

Publication number
TW287949B
TW287949B TW083106428A TW83106428A TW287949B TW 287949 B TW287949 B TW 287949B TW 083106428 A TW083106428 A TW 083106428A TW 83106428 A TW83106428 A TW 83106428A TW 287949 B TW287949 B TW 287949B
Authority
TW
Taiwan
Prior art keywords
inhibitor
products
sequelae
renin
contain
Prior art date
Application number
TW083106428A
Other languages
English (en)
Chinese (zh)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of TW287949B publication Critical patent/TW287949B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/556Angiotensin converting enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
TW083106428A 1993-07-15 1994-07-14 TW287949B (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH213193 1993-07-15

Publications (1)

Publication Number Publication Date
TW287949B true TW287949B (cs) 1996-10-11

Family

ID=4226611

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083106428A TW287949B (cs) 1993-07-15 1994-07-14

Country Status (25)

Country Link
US (1) US5696116A (cs)
EP (1) EP0634175B1 (cs)
JP (1) JP2746537B2 (cs)
KR (1) KR100370181B1 (cs)
CN (1) CN1105573C (cs)
AT (1) ATE198551T1 (cs)
AU (1) AU683262B2 (cs)
BR (1) BR9402815A (cs)
CA (1) CA2128142C (cs)
CZ (1) CZ285413B6 (cs)
DE (1) DE59409631D1 (cs)
DK (1) DK0634175T3 (cs)
ES (1) ES2154277T3 (cs)
GR (1) GR3035702T3 (cs)
HU (1) HU221202B1 (cs)
IL (1) IL110272A (cs)
NO (1) NO312578B1 (cs)
NZ (1) NZ260969A (cs)
PL (1) PL176445B1 (cs)
PT (1) PT634175E (cs)
RU (1) RU2146522C1 (cs)
SA (1) SA94150155B1 (cs)
TW (1) TW287949B (cs)
UA (1) UA27870C2 (cs)
ZA (1) ZA944980B (cs)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
SG87052A1 (en) 1996-02-20 2002-03-19 Bristol Myers Squibb Co Pinacol ester intermediates useful for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
JP4917707B2 (ja) 1997-09-26 2012-04-18 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト エンドセリン拮抗剤およびレニン−アンギオテンシン系阻害剤から成る組合せ剤
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CA2678722C (en) * 1998-07-10 2013-08-27 Novartis Ag Antihypertensive combination of valsartan and a calcium channel blocker
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
CN101011390A (zh) * 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
WO2000056685A1 (en) 1999-03-19 2000-09-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
ES2348646T3 (es) * 2000-08-25 2010-12-10 Research Corporation Technologies, Inc. Aminoacidos anticonvulsionantes para el tratamiento de la neurosis obsesivo-compulsiva.
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
RU2201255C1 (ru) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
JP4519640B2 (ja) * 2002-06-28 2010-08-04 シュペーデル・ファルマ・アーゲー 非ペプチドレニン阻害薬及び界面活性剤を含有する医薬製剤
RU2006108865A (ru) * 2003-08-22 2007-09-27 Шеринг Акциенгезельшафт (De) Производные пиперазина, которые ингибируют хемокины, и их применение для лечения миокардита
CN101312962A (zh) * 2005-12-06 2008-11-26 参天制药株式会社 角膜结膜病变的治疗剂
CA2669535A1 (en) * 2006-12-12 2008-06-19 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorders
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8071596B2 (en) 2007-01-12 2011-12-06 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
PL3658140T3 (pl) * 2017-02-27 2025-09-08 Idorsia Pharmaceuticals Ltd Połączenia aprocitentanu z dodatkowymi składnikami czynnymi do leczenia opornego nadciśnienia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642785A (en) * 1969-08-11 1972-02-15 Merck & Co Inc Indenyl-3-aliphatic amines
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
JPS559058A (en) * 1978-07-06 1980-01-22 Dainippon Pharmaceut Co Ltd 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4470972A (en) * 1981-04-28 1984-09-11 Schering Corporation 7-Carboxyalkylaminoacyl-1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acids
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
AT377496B (de) * 1981-06-19 1985-03-25 Voith Gmbh J M Vorrichtung zum anwickeln einer warenbahn auf eine neu eingelegte wickelhuelse in einer doppeltragwalzen-wickelmaschine
US4410520A (en) * 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
DE3542794A1 (de) * 1985-12-04 1987-06-11 Bayer Ag Antihypertensives kombinationspraeparat
ATE96322T1 (de) * 1988-03-24 1993-11-15 Hoffmann La Roche Antihypertensives kombinationspraeparat.
CA2100171A1 (en) * 1991-01-31 1992-08-01 Kazumi Shiosaki Endothelin converting enzyme inhibitors
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
EP0498722B1 (fr) * 1991-02-07 1997-07-30 Roussel Uclaf Dérivés bicycliques azotés, leur procédé de préparation, les intermédiaires obtenus, leur application comme médicaments et les compositions pharmaceutiques les renfermant
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW216770B (cs) * 1991-07-23 1993-12-01 Hoffmann La Roche
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5420123A (en) * 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists

Also Published As

Publication number Publication date
AU6735794A (en) 1995-01-27
IL110272A0 (en) 1994-10-21
NO942650L (no) 1995-01-16
ZA944980B (en) 1995-02-06
AU683262B2 (en) 1997-11-06
HU9402064D0 (en) 1994-09-28
EP0634175A1 (de) 1995-01-18
CA2128142C (en) 2007-03-06
ES2154277T3 (es) 2001-04-01
CA2128142A1 (en) 1995-01-16
DK0634175T3 (da) 2001-04-30
GR3035702T3 (en) 2001-07-31
PT634175E (pt) 2001-06-29
PL304292A1 (en) 1995-01-23
JP2746537B2 (ja) 1998-05-06
NZ260969A (en) 1996-01-26
BR9402815A (pt) 1995-04-04
HUT67331A (en) 1995-03-28
HU221202B1 (en) 2002-08-28
KR100370181B1 (ko) 2003-04-26
UA27870C2 (uk) 2000-10-16
RU2146522C1 (ru) 2000-03-20
PL176445B1 (pl) 1999-05-31
CN1105573C (zh) 2003-04-16
US5696116A (en) 1997-12-09
NO312578B1 (no) 2002-06-03
NO942650D0 (no) 1994-07-14
SA94150155B1 (ar) 2005-11-15
CZ167794A3 (en) 1995-01-18
ATE198551T1 (de) 2001-01-15
IL110272A (en) 1998-07-15
CN1107364A (zh) 1995-08-30
EP0634175B1 (de) 2001-01-10
KR960013371A (ko) 1996-05-22
CZ285413B6 (cs) 1999-08-11
JPH0753408A (ja) 1995-02-28
DE59409631D1 (de) 2001-02-15
RU94026283A (ru) 1996-05-20

Similar Documents

Publication Publication Date Title
TW287949B (cs)
NO962162D0 (no) Dipeptider som bevirker frigjöring av veksthormon
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
EP0820287A4 (en) THROMBIN INHIBITORS
ZA943744B (en) Therapeutic substituted guanidines
UA27748C2 (uk) Похідні піримідину, що мають активність антагоністів ангіотензину іі, спосіб їх отримання та фармацевтична композиція
AU6452194A (en) Pharmaceutical agents for treatment of emesis
EP1776954A3 (en) The use of inhibitors of the renin-angiotensin system for the treatment of stroke
FI935172A7 (fi) Katepsiini G:n ja elastaasin inhibiittoreita sidekudoksen rappeutumise n ehkäisemistä varten
WO1993000094A3 (en) Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
GB9804886D0 (en) Therapeutic combination
EP0726072A3 (en) Composition for the treatment of hypertension and congestive heart failure, containing an angiotensin II antagonist and an endopeptidase inhibitor
AU4163793A (en) Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease
EP0676951A4 (en) USE OF VITAMIN D GLYCOSIDES FOR THE TREATMENT OR PREVENTION OF OSTEOPOROSIS.
DE59810600D1 (de) Endothelin antagonist und renin-angiotensin system hemmer als kombinationspräparate
UA50761C2 (uk) Спосіб запобігання та/або лікування серцевих захворювань, фармацевтична композиція та спосіб запобігання та/або лікування серцевої недостатності та дисфункції шлуночків в організмі теплокровної тварини
CA2055948A1 (en) Use of a combination of angiotensin-converting enzyme inhibitor and calcium antagonist for the treatment of proteinuria
EP0604853A3 (en) Pharmaceutical composition for preventing or treating arteriosclerosis.
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
AU1506692A (en) Pharmaceutical compositions
ES2106098T3 (es) Lacidipino para el tratamiento de la arteriosclerosis.
IL101540A0 (en) Method and composition for the treatment of herpes related disorders
GR3029492T3 (en) Use of leflunomid for the inhibition of interleukin 1 alpha.
ITFI930163A1 (it) Procedimento, centralina e prodotto per la disinfezione di acque di piscina.

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent